The SPDR S&P Biotech ETF (XBI) climbed 15.6% over the past month while the S&P 500 fell 2.9%, driven by widespread gains across its holdings rather than a few standout stocks. Among the fund's 50 largest positions, 44 rose and only 6 fell, with top contributors including Twist Bioscience, which gained 55.6% and accounts for 2.0% of the fund, uniQure up 88.8% at a 1.1% weight, and Apogee Therapeutics up 70.5% at a 1.3% weight. Together these three stocks contributed about 23% of the fund's total gain, but the rally was broad-based, reflecting the equal-weighted structure of the 157-position portfolio. The move underscores that XBI acts as a proxy for the biotechnology sector, with performance tied to industry-wide sentiment rather than concentrated bets.
Apogee Therapeutics, Inc. Common Stock
Uniqure NV
Twist Bioscience Corp